Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Itvisma Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy CSPA2026D0142B

    Itvisma (onasemnogene abeparvovec-brve) Coverage for Spinal Muscular Atrophy

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CSPA2026D0142B alerts

    Get alerted when Policy CSPA2026D0142B changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This medical benefit drug policy governs prior authorization and coverage of Itvisma for treatment of spinal muscular atrophy in Pennsylvania for eligible patients age 2 years and older who meet the policy's genetic, clinical, administration, and treatment-history requirements.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyItvisma Coverage for Spinal Muscular Atrophy
    Policy CodePolicy CSPA2026D0142B
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation establishing all coverage criteria, including that the patient will not receive routine concomitant SMN-modifying therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The coverage criterion regarding concomitant SMN-modifying therapy was revised to require that the patient not receive routine concomitant therapy, with medical-record review, without stating that current authorizations will be terminated upon Itvisma approval.

    The coverage criterion concerning routine concomitant SMN-modifying therapy was revised.

    1 treatmentMaximum Itvisma treatment per lifetime
    45 daysMaximum authorization duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2+ years
    Minimum patient age
    1:50Maximum anti-AAV9 antibody titer
    2 weeksBaseline HFMSE assessment window
    PAApplicable state

    Coverage Criteria

    Initial Treatment Coverage

    Itvisma is covered for one treatment per lifetime for the treatment of spinal muscular atrophy (SMA) when <strong>all</strong> of the following criteria are met:

    ALL of the following

    • ONE of the following genetic findings is documented:

      • Medical records (e.g., chart notes and laboratory values) confirm a homozygous gene deletion or mutation of the survival motor neuron 1 (SMN1) gene, such as homozygous deletion of exon 7 at locus 5q13.
      • Medical records confirm a compound heterozygous mutation of the SMN1 gene, such as deletion of SMN1 exon 7 (allele 1) and mutation of SMN1 (allele 2).
    • The patient is at least 2 years of age.>= 2 years
    • The patient is not dependent on invasive ventilation or a tracheostomy.
    • Itvisma is prescribed by a neurologist with expertise in the treatment of SMA.
    • The patient is not to receive routine concomitant SMN-modifying therapy, such as Evrysdi (risdiplam) or Spinraza (nusinersen). The patient's medical record will be reviewed.
    • The patient does not have an elevated anti-AAV9 antibody titer above 1:50.<= 1:50
    • The patient will receive prophylactic prednisolone or a glucocorticoid equivalent before and after receipt of Itvisma in accordance with the U.S. Food and Drug Administration (FDA)-approved Itvisma labeling.
    • The patient will receive Itvisma as a single-dose intrathecal injection in accordance with FDA-approved labeling.
    • The patient has never received gene therapy treatment for SMA, including Zolgensma (onasemnogene abeparvovec-xioi) or Itvisma, during the patient's lifetime.
    • The provider does not request a planned inpatient admission for the sole purpose of administering Itvisma.

    Coverage Criteria Revision

    The coverage criterion regarding routine concomitant SMN-modifying therapy was revised effective November 1, 2026.

    The patient is not to receive routine concomitant SMN-modifying therapy, such as Evrysdi (risdiplam) or Spinraza (nusinersen). The patient's medical record will be reviewed.

    Itvisma is not covered when the provider requests a planned inpatient admission for the sole purpose of administering Itvisma.

    Authorization is limited to no more than one Itvisma treatment per lifetime and is issued for no longer than 45 days from approval.

    Itvisma is not proven or medically necessary for the treatment of SMA in patients younger than 2 years of age.

    Itvisma is not proven or medically necessary for SMA without chromosome 5q mutations or deletions.

    Itvisma is not proven or medically necessary for the routine combination treatment of SMA with concomitant SMN-modifying therapy.

    Coding and Coverage Parameters

    Procedure CodeHCPCS
    J3405Injection, onasemnogene abeparvovec-brve, per treatment
    Diagnosis CodesICD-10
    G12.0Infantile spinal muscular atrophy, type I [Werdnig-Hoffmann]
    G12.1Other inherited spinal muscular atrophy
    G12.8Other SMAs and related syndromes
    G12.9Spinal muscular atrophy, unspecified
    G12.25Progressive spinal muscle atrophy
    Patient age
    Minimum eligible age2 years or older
    Younger than 2 yearsTreatment of SMA is not medically necessary
    Applicable conditionSpinal muscular atrophy
    Anti-AAV9 antibody titer
    Maximum allowable titer1:50
    Coverage requirementThe patient must not have an elevated anti-AAV9 antibody titer above 1:50
    Titer above 1:50

    Provider Requirements and Action Items

    Prior Authorization

    Submit prior authorization meeting all criteria

    Prior authorization is required for Itvisma. The request must establish all coverage criteria, including qualifying SMN1-related chromosome 5q disease, age 2 years or older, no disqualifying respiratory dependence or elevated anti-AAV9 antibody titer, prescribing by a neurologist with SMA expertise, no routine concomitant SMN-modifying therapy, no prior SMA gene therapy, FDA-label-consistent administration, and no inpatient admission requested solely for administration.

    Prior Authorization

    Observe lifetime and authorization limits

    Authorization is limited to one treatment per lifetime and no longer than 45 days from approval.

    • More than one Itvisma treatment during the patient's lifetime is not covered.
    • Authorization may not extend beyond 45 days from approval.

    Clinical Background

    Spinal muscular atrophy (SMA) is a rare autosomal recessive neurodegenerative disorder caused primarily by biallelic variants in the SMN1 gene. It is characterized by degeneration of spinal motor neurons, hypotonia, and muscle weakness. Itvisma is an adeno-associated virus vector-based gene therapy administered as a single intrathecal injection for adults and children age 2 years and older with a confirmed SMN1 mutation.

    Definitions

    Homozygous SMN1 deletion or mutation
    DefinitionA homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene
    ExampleHomozygous deletion of SMN1 exon 7
    Chromosomal locusLocus 5q13
    Compound heterozygous SMN1 mutation
    DefinitionA compound heterozygous mutation of the SMN1 gene
    One alleleDeletion of SMN1 exon 7
    Other alleleMutation of SMN1

    Initial Therapy Criteria

    Initial Therapy

    Itvisma is covered for one treatment per lifetime when ALL of the following requirements are met:

    Initial therapy requirements

    • Qualifying SMN1-related chromosome 5q genetic abnormality

      • Medical records confirm a homozygous deletion or mutation of the SMN1 gene, such as homozygous deletion of exon 7 at locus 5q13.
      • Medical records confirm a compound heterozygous SMN1 mutation, such as deletion of SMN1 exon 7 on one allele and mutation of SMN1 on the other allele.
    • Eligibility, clinical, prescribing, administration, and treatment-history requirements

      • The patient is at least 2 years old.>= 2 years

    Quantity Limits

    Quantity limits
    DrugItvisma
    Quantity limitOne treatment per lifetime
    UnitTreatment

    Site of Care and Administration

    Billing Rule

    Administer Itvisma in the office

    Administer Itvisma in the office as a single-dose intrathecal injection in accordance with FDA-approved labeling.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyItvisma Coverage for Spinal Muscular Atrophy
    Policy CodePolicy CSPA2026D0142B
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation establishing all coverage criteria, including that the patient will not receive routine concomitant SMN-modifying therapy.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider Requirements and Action ItemsClinical BackgroundDefinitionsInitial Therapy CriteriaQuantity LimitsSite of Care and Administration
    Coverage may be denied
    Lifetime treatment limit
    Lifetime limit1 treatment per lifetime
    Additional treatmentMore than one Itvisma treatment during the patient's lifetime is not covered
    Prior SMA gene therapyThe patient must never have received gene therapy treatment for SMA in the patient's lifetime
    Authorization duration
    Authorization durationNo longer than 45 days from approval
    Authorization quantityNo more than one treatment per lifetime
    Authorization timingThe 45-day period is measured from approval
    Baseline HFMSE assessment
    AssessmentHammersmith Functional Motor Scale Expanded (HFMSE) baseline functional assessment
    Required timingWithin the 2 weeks prior to Itvisma administration
    Provider requirementThe provider must attest that the assessment will be completed before administration; this is for quality purposes and does not affect the individual coverage decision
    Denial Risk

    Do not use routine concomitant SMN-modifying therapy

    For Itvisma approval, the patient is not to receive routine concomitant SMN-modifying therapy. The patient's medical record will be reviewed.

    • Examples include Evrysdi (risdiplam).
    • Examples include Spinraza (nusinersen).
    Documentation Required

    Submit genetic and treatment-history documentation

    Submit medical records, such as chart notes and laboratory values, confirming the qualifying chromosome 5q genetic abnormality and documenting treatment history.

    • Document a homozygous SMN1 gene deletion or mutation, such as homozygous deletion of exon 7 at locus 5q13; or a compound heterozygous SMN1 mutation.
    • Document that the patient has never received SMA gene therapy, including Zolgensma or Itvisma.
    Documentation Required

    Attest to required HFMSE assessments

    The provider must attest that an HFMSE baseline functional assessment will be completed within the 2 weeks before Itvisma administration and that HFMSE assessments will be performed during subsequent office visits.

    • These attestations are for quality purposes and do not affect the individual coverage determination.
    Documentation Required

    Ensure the medical record supports therapy review

    The patient's medical record will be reviewed to assess routine concomitant SMN-modifying therapy.

    Denial Risk

    Screen for clinical and administration exclusions

    Coverage may be denied when the patient is dependent on invasive ventilation or has a tracheostomy, has an elevated anti-AAV9 antibody titer above 1:50, has previously received SMA gene therapy, receives routine concomitant SMN-modifying therapy, or the requested administration is a planned inpatient admission solely for Itvisma administration.

    • The patient must have an anti-AAV9 antibody titer of no more than 1:50.
    • The patient must not have previously received Zolgensma or Itvisma for SMA.
    Denial Risk

    Avoid non-medically necessary treatment scenarios

    Itvisma is not proven or medically necessary for SMA in patients younger than 2 years, SMA without chromosome 5q mutations or deletions, or routine combination treatment with concomitant SMN-modifying therapy.

    • Confirm the patient is at least 2 years of age.
    • Confirm a qualifying chromosome 5q mutation or deletion.
    • Do not request routine combination treatment with concomitant SMN-modifying therapy.
    Hammersmith Functional Motor Scale Expanded (HFMSE)
    MeasureA measure of motor functional abilities in children and adults with SMA
    Number of items33
    Maximum total score66
    Score interpretationHigher scores indicate better motor function
  1. The patient is not dependent on invasive ventilation or tracheostomy.
  2. Treatment is prescribed by a neurologist with expertise in SMA.
  3. The patient is not to receive routine concomitant SMN-modifying therapy, such as Evrysdi (risdiplam) or Spinraza (nusinersen).
  4. The patient's anti-AAV9 antibody titer is no more than 1:50.<= 1:50
  5. The patient will receive prophylactic prednisolone or a glucocorticoid equivalent before and after treatment in accordance with FDA-approved Itvisma labeling.
  6. Itvisma will be administered as a single-dose intrathecal injection in accordance with FDA-approved labeling.
  7. The patient has not previously received SMA gene therapy, including Zolgensma or Itvisma.
  8. The provider is not requesting a planned inpatient admission solely for Itvisma administration.
  9. Only one Itvisma treatment is authorized during the patient's lifetime.1 treatment per lifetime

    Authorization may be issued for no longer than 45 days from approval.

  10. Concomitant Therapy Requirement

    The revised criteria require ALL of the following:

    No routine concomitant SMN-modifying therapy

    • The patient is not to receive routine concomitant SMN-modifying therapy, such as Evrysdi (risdiplam) or Spinraza (nusinersen); the patient's medical record will be reviewed.

      The current criterion no longer states that existing SMN-modifying therapy authorizations will be terminated upon Itvisma approval.